© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Gordon A. Brown, DO, presents the case of a man with prostate cancer, reviews available treatment options, and discusses data on combination androgen deprivation therapy/apalutamide in patients with metastatic castration-sensitive prostate cancer.
July 19th 2022
Gordon A. Brown, DO, presents the profile of a 60-year-old man with prostate cancer.
An expert comments on the patient profile and offers insights into how he approaches treatment and management of prostate cancer.
Dr Gordon Brown provides an overview of single-agent androgen deprivation therapy (ADT) and other regimens that may be used in combination with ADT, including androgen receptor (AR) inhibitors, for treatment of mCSPC.
A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.
Gordon A. Brown, DO, comments on adverse events observed after combination ADT/apalutamide treatment and how they might be managed.
A comparison of the safety and efficacy of available AR inhibitors and a discussion of factors that impact treatment selection in mCSPC.
Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.